American Association for Cancer Research’s Virtual Annual Meeting – April 27-28, 2020
|Karus Therapeutics Ltd., of Oxfordshire, U.K.||KA-2507||HDAC6 inhibitor||Advanced cancer||Phase I data in patients for whom no standard of care was available showed drug well-tolerated at all doses tested, with evidence of selective target engagement at all exposure levels|
|Noxxon Pharma NV, of Berlin||NOX-A12||CXCL12 inhibitor||Microsatellite-stable, metastatic colorectal or pancreatic cancer||Phase I/II results show combination with Keytruda (pembrolizumab, Merck & Co. Inc.) produced stable disease in 25% of patients and prolonged time on treatment vs. prior therapy for 35%; comparison of tumor biopsies from before and after NOX-A12 monotherapy showed trend toward agglomeration of T cells within tumors in about half of patients where NOX-A12 had induced a Th1-type cytokine response|
|Oric Pharmaceuticals Inc., of South San Francisco||ORIC-533||Small-molecule inhibitor of CD73||Cancer||Preclinical data demonstrated more potent adenosine inhibition compared to an antibody approach; further studies showed CD73 inhibition impacted T-cell proliferation and cytokine production in the context of adenosine-mediated immunosuppression; ORIC-533 demonstrated significant antitumor single-agent efficacy when dosed once a day, with corresponding reduction of adenosine levels in the tumor microenvironment|
|Syndax Pharmaceuticals Inc., of Waltham, Mass.||SNDS-5613||Oral menin inhibitor||Genetically defined acute leukemias||Data from phase I portion of phase I/II Augment-101 study, from 6 patients treated at increasing dose levels showed responses observed in 2 of 3 harboring an MLL rearrangement, including 1 whose drug exposure was consistent with that needed for activity in preclinical models, who had a complete response with incomplete blood count recovery after 28 days and subsequently improved to complete response; second patient achieved a partial response with incomplete blood count recovery after 28 days|
|Tarveda Therapeutics Inc., of Watertown, Mass.||PEN-866||Hsp90 binding miniature drug conjugate||Solid tumor malignancies||Data from phase I study showed confirmatory pharmacokinetics in patient plasma and highlighted data from 2 patient biopsies, which confirmed higher concentrated levels of the PEN-866 conjugate and SN-38 payload in tumor relative to plasma; PEN-866 plasma concentrations up to 39 µg/mL and area under the concentration curve of 57 h·µg/mL were achieved and determined for the recommended phase IIa dose|
|Trovagene Inc., of San Diego||Onvansertib||Third-generation, oral ATP competitive inhibitor of serine/threonine polo-like-kinase 1 enzyme||KRAS-mutated metastatic colorectal cancer||Data from phase I/II trial in combination with FOLFIRI and Avastin (bevacizumab, Roche Holding AG) for second-line treatment showed 88% response in 7 of 8 evaluable patients, to date, with 3 showing partial response and 4 with stable disease; median progression-free survival of at least 6.5 months, with 6 patients continuing treatment to date|
For more information about individual companies and/or products, see Cortellis.